Astria licenses navenibart HAE rights in Japan to Kaken for $16M upfront + milestones

Astria Therapeutics, Inc.

Upfront payment of $16M; potential $16M in milestones; tiered royalties up to 30% on Japan sales.
Kaken to support ALPHA-ORBIT Phase 3 trial in Japan, handle regulatory submissions, reimburse partial Phase 3 costs.
Cash runway extended into 2028 based on current operating plan including navenibart Phase 3 and STAR-0310 Phase 1a.
Astria retains rights outside Japan; Kaken gets right of first negotiation for other indications.
Deal structured as exclusive license for development and commercialization of navenibart for HAE prevention in Japan.

item 1.01item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.